Get the Stockscreener App
4.94
1.00%
-0.05
After Hours:
4.91
-0.03
-0.61%
Vanda Pharmaceuticals Inc stock is traded at $4.94, with a volume of 315.57K.
It is down -1.00% in the last 24 hours and up +8.57% over the past month.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
See More
Previous Close:
$4.99
Open:
$5.04
24h Volume:
315.57K
Relative Volume:
0.51
Market Cap:
$288.08M
Revenue:
$192.64M
Net Income/Loss:
$2.51M
P/E Ratio:
94.27
EPS:
0.0524
Net Cash Flow:
$12.42M
1W Performance:
-0.20%
1M Performance:
+8.57%
6M Performance:
+6.24%
1Y Performance:
+31.38%
1-Day Range:
$4.85
$5.04
1-Week Range:
$4.835
$5.155
52-Week Range:
$3.71
$6.75
Vanda Pharmaceuticals Inc Stock (VNDA) Company Profile
Name
Vanda Pharmaceuticals Inc
Sector
Industry
Phone
202-734-3400
Address
2200 PENNSYLVANIA AVE NW, WASHINGTON
Compare VNDA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VNDA
Vanda Pharmaceuticals Inc
|
4.94 | 288.08M | 192.64M | 2.51M | 12.42M | 0.0524 |
|
VRTX
Vertex Pharmaceuticals Inc
|
512.52 | 131.61B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.36 | 73.51B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
619.97 | 37.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.44 | 32.81B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
266.26 | 28.62B | 3.81B | -644.79M | -669.77M | -6.24 |
Vanda Pharmaceuticals Inc Stock (VNDA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-31-24 | Initiated | H.C. Wainwright | Buy |
| Jul-11-24 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-25-22 | Downgrade | Jefferies | Buy → Hold |
| May-12-21 | Initiated | BofA Securities | Buy |
| Jan-14-21 | Downgrade | Citigroup | Buy → Neutral |
| Oct-29-20 | Upgrade | Citigroup | Neutral → Buy |
| Jun-09-20 | Downgrade | Citigroup | Buy → Neutral |
| Mar-16-20 | Downgrade | Oppenheimer | Perform → Underperform |
| Mar-12-20 | Upgrade | Citigroup | Neutral → Buy |
| Nov-07-19 | Downgrade | Citigroup | Buy → Neutral |
| Aug-01-19 | Upgrade | Citigroup | Neutral → Buy |
| Jul-25-19 | Downgrade | Stifel | Buy → Hold |
| Dec-11-18 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-04-18 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Dec-04-18 | Reiterated | Jefferies | Buy |
| Nov-08-18 | Resumed | Jefferies | Buy |
| Sep-21-18 | Resumed | Oppenheimer | Outperform |
| May-23-18 | Initiated | Citigroup | Buy |
| Jan-19-18 | Initiated | Seaport Global Securities | Buy |
| Sep-14-17 | Reiterated | Piper Jaffray | Overweight |
| Jun-27-17 | Resumed | Piper Jaffray | Overweight |
| May-26-17 | Initiated | H.C. Wainwright | Buy |
| Apr-12-17 | Initiated | Oppenheimer | Outperform |
| Nov-09-16 | Initiated | Aegis Capital | Buy |
| Oct-06-16 | Resumed | Jefferies | Buy |
View All
Vanda Pharmaceuticals Inc Stock (VNDA) Latest News
Vanda Raises Concerns Over FDA Review Timeline for Motion Sickness Therapy Candidate - Marketscreener.com
Vanda Pharmaceuticals announces FDA review date for new drug By Investing.com - Investing.com South Africa
Vanda Pharmaceuticals’ New Drug Application Accepted by FDA - TipRanks
Vanda Pharmaceuticals announces FDA review date for new drug - Investing.com
Insider Buying: Mihael Polymeropoulos Acquires Additional Shares of Vanda Pharmaceuticals Inc (VNDA) - GuruFocus.com
Insider Buying: Mihael Polymeropoulos Acquires 10,000 Shares of Vanda Pharmaceuticals Inc (VNDA) - GuruFocus.com
CLASS ACTION UPDATE for VNDA, CTL and INGN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders - ACCESS Newswire
CLASS ACTION UPDATE for AVEO, KHC and VNDA: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders - ACCESS Newswire
Vanda Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Vanda Pharmaceuticals Inc. to Host Earnings Call - ACCESS Newswire
Vanda Pharmaceuticals CEO Mihael Polymeropoulos buys $50,150 in stock By Investing.com - Investing.com South Africa
Vanda Pharmaceuticals CEO Mihael Polymeropoulos buys $50,150 in stock - Investing.com India
President and CEO Polymeropoulos Mihael Hristos bought $50,150 worth of shares (10,000 units at $5.01), increasing direct ownership by 0.44% to 2,295,731 units (SEC Form 4) - Quantisnow
CLASS ACTION UPDATE for AVEO, DPLO and VNDA: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders - ACCESS Newswire
Vanda Pharmaceuticals CEO Mihael Polymeropoulos acquires $50,200 in stock By Investing.com - Investing.com Australia
US FDA Spikes Vanda’s Hetlioz For Insomnia, Lack Of Well-Controlled Trial ‘Fatal’ - Citeline News & Insights
Vanda Pharmaceuticals CEO Mihael Polymeropoulos acquires $50,200 in stock - Investing.com India
President and CEO Polymeropoulos Mihael Hristos bought $50,200 worth of shares (10,000 units at $5.02), increasing direct ownership by 0.44% to 2,285,731 units (SEC Form 4) - Quantisnow
President and CEO Polymeropoulos Mihael Hristos covered exercise/tax liability with 95,999 shares and bought $47,050 worth of shares (10,000 units at $4.71), decreasing direct ownership by 4% to 2,275,731 units (SEC Form 4) - Quantisnow
CLASS ACTION UPDATE for TYME, GE and VNDA: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders - ACCESS Newswire
Allspring Global Investments Holdings LLC Sells 77,738 Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) - MarketBeat
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) CEO Mihael Hristos Polymeropoulos Purchases 10,000 Shares - MarketBeat
Vanda Pharmaceuticals CEO acquires $47,600 in common stock By Investing.com - Investing.com Australia
Vanda Pharmaceuticals CEO acquires $47,600 in common stock - Investing.com India
President and CEO Polymeropoulos Mihael Hristos bought $47,600 worth of shares (10,000 units at $4.76), increasing direct ownership by 0.43% to 2,361,730 units (SEC Form 4) - Quantisnow
US High Growth Tech Stocks With Strong Potential - Yahoo Finance UK
Investor Network: Vanda Pharmaceuticals Inc. to Host Earnings Call - ACCESS Newswire
February 2025 Penny Stocks To Keep An Eye On - Simply Wall St
Vanda Pharmaceuticals CEO Mihael Polymeropoulos purchases $47,650 in stock By Investing.com - Investing.com South Africa
Vanda Pharmaceuticals CEO Mihael Polymeropoulos purchases $47,650 in stock - Investing.com India
President and CEO Polymeropoulos Mihael Hristos bought $47,650 worth of shares (10,000 units at $4.76), increasing direct ownership by 0.43% to 2,341,730 units (SEC Form 4) - Quantisnow
Vanda Pharmaceuticals CEO Mihael Polymeropoulos purchases $44,640 in stock By Investing.com - Investing.com South Africa
Vanda Pharmaceuticals CEO Mihael Polymeropoulos purchases $44,640 in stock - Investing.com India
President and CEO Polymeropoulos Mihael Hristos bought $44,640 worth of shares (10,000 units at $4.46), increasing direct ownership by 0.43% to 2,331,730 units (SEC Form 4) - Quantisnow
Vanda Falls Again As Teva, US FDA Win Judgment In Tasimelteon Approval Case - Citeline News & Insights
Vanda Pharmaceuticals CFO Kevin Moran purchases $8,778 in stock By Investing.com - Investing.com Nigeria
Vanda Pharmaceuticals develops ASO therapy for rare disease By Investing.com - Investing.com Australia
Vanda Pharmaceuticals CFO Kevin Moran purchases $8,778 in stock - Investing.com India
SVP, CFO & Treasurer Moran Kevin Patrick bought $8,779 worth of shares (2,000 units at $4.39), increasing direct ownership by 0.57% to 355,763 units (SEC Form 4) - Quantisnow
Vanda Pharmaceuticals develops ASO therapy for rare disease - Investing.com India
Vanda Pharmaceuticals Inc Stock (VNDA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):